SB 1214 Arizona Senate · 57th Legislature - Second Regular Session

stem cells; birth tissue; therapy

SB 1214 restricts Arizona physicians from using stem cells or birth tissue derived from aborted fetuses or embryos for therapy. It allows non-FDA-approved stem cell or birth tissue therapies only for orthopedics, wound care, or pain management, provided the cells come from FDA-registered or certified facilities (like blood banks or tissue banks) and meet specific safety and viability standards. The bill requires physicians to disclose in advertising and obtain detailed informed consent stating the therapy isn't FDA-approved, and mandates facilities to provide full certification details to physicians. These provisions directly affect medical providers, clinics, and tissue suppliers offering such therapies in Arizona.

Issues: ✗ Healthcare

Bill status vetoed 4 of 5 stages cleared

Introduction

Jan 2026

Committee Review

Feb 2026

Senate Passage

Jun 2026

House Passage

Jun 2026

Vetoed

Jun 2026

Introduced Jan 20, 2026 Vetoed Jun 19, 2026

Maddy AI version diff · 2 comparisons

What changed between versions

Introduced Version → House Engrossed Version (06/09/2026) · 7 edits · Mar 4, 2026

MODERATE

The bill was significantly rewritten to broaden its scope from 'stem cell and birth tissue therapy' to 'stem cell and regenerative therapy,' removing the specific limitation that treatments must be for orthopedics, wound care, or pain management. The language was updated to apply to all licensed health professionals ('providers') rather than just physicians, and the definition of covered materials was expanded to include exosomes and biologic materials derived from adult donors or afterbirth. The bill also added new requirements for providers to maintain treatment records, report adverse events, and submit de-identified data to clinical registries.

Scope change

The bill's scope expanded from specific medical specialties (orthopedics, wound care, pain management) to all licensed health professionals providing stem cell or regenerative therapies.

SCOPE

Removed the restriction limiting therapy to orthopedics, wound care, or pain management, allowing broader application of the law.

ELIGIBILITY

Changed the subject from 'physicians' to 'providers,' expanding eligibility to include all health professionals licensed to perform these therapies.

DEFINITION

Added 'exosomes' and 'biologic materials' to the list of covered therapeutic materials.

Replaced the specific definition of 'birth tissue therapy' with the broader term 'stem cell or regenerative therapy' and updated the definition of covered materials.

REQUIREMENT

Added new mandates for providers to maintain accurate treatment records, document outcomes, and report adverse events to regulatory boards and suppliers.

Added a requirement for providers to voluntarily submit de-identified patient data to professional clinical registries.

Updated facility accreditation requirements to include the American Academy of Stem Cell Medicine as an approved accrediting body.

Floor votes · House Jun 9, 2026

How they voted

This bill passed the Senate by voice vote (no roll call recorded).

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Amendments

Jun 19, 2026

Vetoed

Vetoed by Governor

executive

Jun 12, 2026

Upper · Passed

PASSED

upper

Jun 11, 2026

Upper · Passed

PASSED

upper

Jun 9, 2026

Lower · Passed

PASSED

lower

May 5, 2026

Lower · Passed

DPA

lower

May 5, 2026

Lower · Passed

PASSED

lower

Apr 21, 2026

Lower · Passed

PASSED

lower

Apr 14, 2026

Lower · Passed

DPA

lower

Mar 23, 2026

Lower · Passed

DPA

lower

Mar 4, 2026

Upper · Passed

PASSED

upper

Mar 4, 2026

Upper · Passed

DPA

upper

Feb 18, 2026

Upper · Passed

upper

1 primary · 0 co-sponsors